ReachMD

Episodes 1-15 of 98

• • 

    

    Justin Gainor, MD

    Peer

  1

  

  RestartResume

  What is the Recommended Monitoring Plan for Patients Receiving RET-Targeted Therapies?

  What is the Recommended Monitoring Plan for Patients Receiving RET-Targeted Therapies?

  1.00 program credits

• • 

    

    Justin Gainor, MD

    Peer

  1

  

  RestartResume

  What is the Preferred Molecular Testing Method to Detect RET in NSCLC?

  What is the Preferred Molecular Testing Method to Detect RET in NSCLC?

  1.00 program credits

• • 

    

    Alexander Drilon, MD

    Peer

  1

  

  RestartResume

  Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung Cancers

  Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung Cancers

  1.00 program credits

• • 

    

    Alexander Drilon, MD

    Peer

  1

  

  RestartResume

  Side-Effects of RET-Directed Targeted Therapy

  Side-Effects of RET-Directed Targeted Therapy

  1.00 program credits

• • 

    

    Justin Gainor, MD

    Peer

  • 

    

    Alexander Drilon, MD

    Peer

  2

  

  RestartResume

  Selecting and Managing RET-Targeted Therapy in mNSCLC

  Selecting and Managing RET-Targeted Therapy in mNSCLC

  1.00 program credits

• • 

    

    Alexander Drilon, MD

    Peer

  2

  

  RestartResume

  Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

  Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

  1.00 program credits

• • 

    

    Justin Gainor, MD

    Peer

  1

  

  RestartResume

  Can I Use Targeted Therapy in RET-Positive mNSCLC in Pretreated Patients?

  Can I Use Targeted Therapy in RET-Positive mNSCLC in Pretreated Patients?

  1.00 program credits

• • 

    

    Justin Gainor, MD

    Peer

  • 

    

    Alexander Drilon, MD

    Peer

  3

  

  REThink Treatment of NSCLC: Optimizing Care Through Early Genomic Testing and Targeted Treatment

  1.00 credits 7 episodes

• • 

    

    Benjamin Levy, MD

    Peer

  • 

    

    Rebecca Heist, MD, MPH

    Peer

  • 

    

    Peter Bela Illei, MD

    Peer

  0

  

  RestartResume

  TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use

  TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use

  0.50 credits

• • 

    

    Jyoti D. Patel, MD, FASCO

    Peer

  1

  

  RestartResume

  Patient-Centered Discussions and Shared Decision-Making in the Management of NSCLC with METex14 Skipping Mutations

  Patient-Centered Discussions and Shared Decision-Making in the Management of NSCLC with METex14 Skipping Mutations

  0.25 credits

• • 

    

    Paul Paik, MD

    Peer

  • 

    

    Catherine Shu, MD

    Peer

  2

  

  RestartResume

  Evaluating Your Current Options in the Treatment of NSCLC with METex14 Skipping Mutations

  Evaluating Your Current Options in the Treatment of NSCLC with METex14 Skipping Mutations

  0.25 credits

• • 

    

    Jean M. Elwing, MD

    Peer

  • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  • 

    

    Joseph Kay, MD

    Peer

  1

  

  RestartResume

  Opening Statements - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Opening Statements - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  1.00 program credits

• • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  • 

    

    Joseph Kay, MD

    Peer

  2

  

  RestartResume

  Closing Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Closing Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  1.00 program credits

• • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  • 

    

    Alexander Opotowsky, MD, MMSc

    Peer

  • 

    

    Joseph Kay, MD

    Peer

  1

  

  RestartResume

  Prosecution’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Prosecution’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  1.00 program credits

• • 

    

    Joseph Kay, MD

    Peer

  • 

    

    Wayne J. Franklin, MD, FACC

    Peer

  • 

    

    Richard Krasuski, MD

    Peer

  • 

    

    Jamil A. Aboulhosn, MD

    Peer

  1

  

  RestartResume

  Defense’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  Defense’s Arguments - Holding Court in PH: Should All Adult Fontan Patients Be Placed on PAH Group 1 Therapy? 

  1.00 program credits

• 1
• 2
• 3
• …
• 6
• 7
• Next